期刊文献+

儿科鲍氏不动杆菌感染的危险因素与耐药性研究

Risk factors and drug resistance for children with Acinetobacter baumannii infection
原文传递
导出
摘要 目的调查医院儿科患儿鲍氏不动杆菌感染情况、感染危险因素及耐药性,为儿科鲍氏不动杆菌感染的临床预防治疗提供参考依据。方法选取医院2012年12月-2015年12月儿科收治的患儿3 222例为研究对象,分离、培养并鉴定患儿的病原菌种类,对检出的鲍氏不动杆菌进行药敏试验,数据采用SPSS 19.0软件进行统计分析。结果 3 222例患儿样本中共培养出病原菌471株,以革兰阴性菌为主,共278株占59.02%;鲍氏不动杆菌是最主要的病原菌,占16.56%;机械通气、气管插管、抗菌药物使用时间和导尿管留置是患儿感染鲍氏不动杆菌的危险因素(P<0.05);鲍氏不动杆菌对氨曲南的耐药率最高,为97.44%。结论鲍氏不动杆菌是导致儿科感染的最主要病原菌,其对氨曲南的耐药率较高,对亚胺培南的耐药率较低,临床上应根据上述结果指导实施诊治。 OBJECTIVE To investigate the infection situation,risk factors and drug resistance for children with Acinetobacter baumannii in the hospital,so as to provide basis for the prevention of children with A.baumannii infection.METHODS A total of 3222 cases of patients in the department of pediatrics of the hospital from Dec.2012 to Dec.2015 were chosen as research objects.The pathogens were isolated,cultured and identified,and the detected A.baumannii were taken for susceptibility test.The data were analyzed by SPSS 19.0.RESULTS Totally 471 strains of pathogens were cultured in the 3222 cases of children samples,and mainly were 278 strains of gram-negative bacteria,accounting for 59.02%.A.baumannii was the main pathogen,accounting for 16.56%.The risk factors for children with A.baumannii infection were mechanical ventilation,endotracheal intubation,usage time of antibiotics and catheter indwelling(P〈0.05).The resistant rate of A.baumannii to aztreonam was97.44%,which is the highest.CONCLUSION A.baumannii is the most important cause of pediatric infectious,it has a higher resistant rate to aztreonam,and a lower resistance rate to imipenem,so we should guide the implementation of clinical diagnosis and treatment based on the results.
出处 《中华医院感染学杂志》 CAS CSCD 北大核心 2016年第24期5695-5697,共3页 Chinese Journal of Nosocomiology
基金 河南省科技厅科技发展计划(14A320012)
关键词 儿科 鲍氏不动杆菌感染 危险因素 耐药性 Pediatrics Acinetobacter baumannii infection Risk factors Drug resistance
  • 相关文献

参考文献2

二级参考文献24

  • 1卫生部办公厅.多重耐药菌医院感染预防与控制技术指南(试行).2011-01-17.
  • 2American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare- associated pneumonia[J]. Am J Respir Crit Care Med, 2005, 171(4): 388-416.
  • 3Zavascki A P, Carvalhaes C G, Picoo R C, et al. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii:resistance mechanisms and implications for therapy[J]. Expert Rev Anti Infect Ther, 2010, 8(1): 71-93.
  • 4Karageorgopoulos D E, Kelesidis T, Kelesidis I, et al. Tigecycline for the treatment of multidrug- resistant(including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence[J]. J Antimicrob Chemother, 2008, 62(1): 45-55.
  • 5Guner R, Hasanoglu I, Keske S, et al. Outcomes in patients infected with carbapenem-resistant Acinetobacter baurnannii and treated with tigecycline alone or in combination therapy[J]. Infection, 201 I, 39(6): 515-518.
  • 6Gallagher J C, Rouse H M. Tigecycline for the treatment of Acinetobaeter infections: a case series[J]. Ann Pharmacother, 2008, 42(9): 1188- 1194.
  • 7Gordon N C, Wareham D W. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline[J]. J Antimicrobial Chemother, 2009, 63(4): 775-780.
  • 8Shin J A, Chang Y S, Kim H J, et al. Clinical outcomes of tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii infection[J]. Yonsei Med J, 2012, 53(5): 974-984.
  • 9De Pascale G, Montini L, Pennisi M, et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria[J]. Criti Care, 2014, 18(3): R90.
  • 10汪复,朱德妹,胡付品,阮斐怡,倪语星,孙景勇,徐英春,张小江,胡云健,艾效曼,俞云松,杨青,孙自镛,简翠,贾蓓,黄文祥,卓超,苏丹虹,魏莲花,吴玲,张朝霞,季萍,王传清,薛建昌,张泓,李万华.2008年中国CHINET细菌耐药性监测[J].中国感染与化疗杂志,2009,9(5):321-329. 被引量:422

共引文献84

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部